Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
about
Targeting Oncogenic Mutant p53 for Cancer TherapyEpigenetic treatment of solid tumours: a review of clinical trialsLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesNovel systemic therapy against malignant pleural mesothelioma.BAP1, a tumor suppressor gene driving malignant mesothelioma.Targeting the epigenome in malignant pleural mesotheliomaA Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor TherapyCrosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells.Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.Optimal Therapy of Advanced Stage Mesothelioma.A catalogue of treatment and technologies for malignant pleural mesothelioma.Advances in treatment of mesothelioma.BAP1 mutations in high-grade meningioma: implications for patient care.Malignant Mesothelioma: Time to Translate?Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cellsAdvances in systemic therapy for malignant mesothelioma: future perspectives.A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.Medical treatment of malignant pleural mesothelioma relapses.Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.Malignant pleural mesothelioma: some progress, but still a long way from cure.
P2860
Q26770856-5AC38B31-665B-404F-A918-B5E27CC61B6DQ26773803-D6E4D3D6-0450-41DC-A246-69342F222A65Q28395597-AA1C9DF7-390F-4CD4-BF8E-91F31D2083AEQ33890499-42BE1FC0-4851-491D-BB64-55D0A7A2B57CQ33890512-BD13AB5F-72A5-468F-B05C-878F430565EEQ33890546-0871CD19-5B7C-4607-B32B-7518D48C3A00Q35883829-C68FE7A8-B57B-41F0-BDD0-A6AB1FE5CE86Q36009462-1D72684E-308E-4F8A-AAC3-20C134AE7E5BQ36882942-5209C2AE-B3D2-48F2-9E07-5FA2AA27B730Q37619779-76E16CA5-A42B-4D40-9AC2-28662CAFCA2CQ38586323-370B8651-FBEE-4ECA-A180-F60A791B3FC4Q38633115-53ADF69B-9E62-44D4-882C-DB91BD3CA200Q38662242-2FEFBDFA-9429-46B4-8E0F-6036014C7E70Q38760623-D828CF4C-D965-438F-B261-EAD0395F67EAQ38800916-C5A6BFBE-911E-495C-8E05-AA4477FBAEEEQ39290955-5439C058-7F64-4F7C-A895-F0BC853200DCQ39366003-5E418883-03F3-4427-A796-F16EEE8A9EC9Q42728294-3745BDDC-4B20-45B6-8E75-C7E338DE31F8Q42835134-D8E37273-0D63-48D2-87A4-4FF19FBBE486Q47912434-F433F502-831B-4DAE-9E85-FC94172E7300Q51402069-83B0FD32-E791-4159-B2DA-FD33D0C1BBB7Q52579899-FCD2F5EB-1026-4817-A443-D18E1A94EC5CQ52642770-135A5875-6658-4414-9A29-3D767E83F131Q52672887-73C2A6DA-161F-470A-98B1-3854F9A5C39FQ52672891-E896E05B-AABA-437A-B6F4-A8BAA5553D96Q55064382-4FAD458F-6521-40F5-B32C-1765347EE7EC
P2860
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@en
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@nl
type
label
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@en
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@nl
prefLabel
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@en
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@nl
P2093
P921
P1433
P1476
Vorinostat in patients with ad ...... sed, placebo-controlled trial.
@en
P2093
Anne S Tsao
Christian Manegold
Dean Fennell
Gregory M Lubiniecki
Gunnar Hillerdal
Hedy L Kindler
Hilary Calvert
Jean-Jacques Lafitte
Kazuya Fukuoka
Lee M Krug
P304
P356
10.1016/S1470-2045(15)70056-2
P577
2015-03-20T00:00:00Z